• For Institutions

  • Download
  • Help
  • About

longbridgelongbridge
longbridgelongbridge
Products
Pricing
Markets
Global Markets
Stock Screener
Information
Insights
News
Live
Academy
Affiliate Program
Promotions
PortAI
EN
English
简体中文
繁體中文
繁體中文(廣東話)Posts & comments will be shown in Cantonese
Search...
Quote ListQuote List
Overview
News
Financials
© 2025 Longbridge|Disclaimer

Event Tracking

Nov14
Spero Therap released FY2025 Q3 earnings on November 13 After-Market EST, with actual revenue of USD 5.442 M (forecast USD 0) and actual EPS of USD -0.1311 (forecast USD -0.25)
00:00
Spero Therap released FY2025 9 Months earnings on November 13 After-Market (EST), actual revenue USD 25.51 M, actual EPS USD -0.4119
00:00
Nov6
Spero Therapeutics to Release FY2025 Q3 Earnings on November 13 After-Market (EST), Forecast EPS -0.25 USD
00:25
Oct21
Spero Therapeutics and GSK Announce Positive Results for tebipenem HBr Phase III Trial
06:00
Aug12
Spero Therap released FY2025 Semi-Annual Earnings on August 12 After-Market (EST), Actual Revenue: USD 20.06M, Actual EPS: USD -0.2794
23:00
Spero Therap released FY2025 Q2 earnings on August 12 After-Market EST: Actual Revenue USD 14.19 M (Forecast USD 0), Actual EPS USD -0.0303 (Forecast USD -0.38)
23:00

Schedules & Filings

Schedules
Filings
Nov13
Earning Release(EST)

FY2025 Q3 Earning Release (USD) Revenue 5.442 M, Net Income -7.382 M, EPS -0.1311

Aug12
Earning Release(EST)

FY2025 Q2 Earning Release (USD) Revenue 14.19 M, Net Income -1.7 M, EPS -0.0303

May13
Earning Release(EST)

FY2025 Q1 Earning Release (USD) Revenue 5.874 M, Net Income -13.87 M, EPS -0.2503

View More

Stock List

Top Gainers
Top Decliners
China Concepts
Symbol
Price
%Chg
Change
MSOX
7.940
+107.85%
+4.120
YCBD
1.200
+90.17%
+0.569
THH
15.520
+57.72%
+5.680
WEED
25.325
+55.65%
+9.055
NCI
1.920
+54.84%
+0.680
CNBS
34.820
+54.57%
+12.293
MSOS
5.800
+54.26%
+2.040
CGC
1.740
+53.98%
+0.610
RYM
23.800
+47.73%
+7.690
TLRY
12.150
+44.13%
+3.720
View More